Voyageur Pharmaceuticals is advancing its vertically integrated strategy for barium and iodine contrast media. The company is currently completing Bankable Feasibility Studies (BFS) for its Frances Creek barium project and its iodine production initiatives, while also pursuing FDA regulatory pathways.
Voyageur Pharmaceuticals has confirmed that its Frances Creek barite meets pharmaceutical-grade purity standards, with an average BaSO4 assay of 98.8%. The company is progressing toward Health Canada human trials and has secured non-dilutive funding through the Alberta Innovates program.
Voyageur Pharmaceuticals has commenced its first commercial shipments of Health Canada-approved barium contrast products to Canadian clinics. The company also highlighted its Frances Creek Project in British Columbia, which contains a 121,000-tonne indicated and inferred barium sulfate resource.
Voyageur Pharmaceuticals has announced its first commercial sale of barium contrast agents, totaling C$89,000. The company also highlighted its 120,000-tonne Frances Creek barium sulfate resource in British Columbia, valued at C$344M.
